ELDN Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. The company's lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). It also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/17/2014
Outstanding shares:  14,306,788
Average volume:  92,544
Market cap:   $59,373,170
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    28617K101
ISIN:        US28617K1016
Valuation   (See tab for details)
PE ratio:   -3.99
PB ratio:   0.34
PS ratio:   247.39
Return on equity:   -39.03%
Net income %:   -27,765.42%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy